RANCOR (ranolazine) is commonly used for managing symptoms associated with chronic stable angina pectoris, focusing on providing supportive relief from recurrent chest discomfort and assisting with a patient's overall functional stability. It is generally used as add-on therapy.

The medication is relevant for conditions involving episodic or fluctuating manifestations of heart-related chest pain. It helps address symptom clusters that include the frequency and intensity of predictable, activity-related episodes of chest pain, pressure, or tightness, which is a key characteristic of stable angina.

This symptomatic relief assists with maintaining functional stability and may help patients cope more steadily with the exertion required for routine activities. The treatment is often applied in scenarios where additional management of discomfort is required, such as when symptoms remain inadequately controlled despite the use of other standard anti-anginal drugs, or when patients cannot tolerate those conventional treatments.

“Its purpose in symptomatic management is to ease the overall symptom load and support patients during episodes of heightened discomfort.”

Quick Fact: Relief for Recurrent Chest Discomfort RANCOR supports the management of long-term, stable chest pain symptoms, contributing to improved comfort and assists with maintaining functional stability during symptomatic periods.

The eligibility profile for РАНКОФ (ranolazine) is defined by regulatory documents, establishing clear limitations on who may use the medicine. It is indicated for use exclusively in the adult population (age 18 and older).

Population Status	Regulatory Eligibility Rule
Absolute Contraindications	Use is strictly contraindicated in patients with severe renal impairment (Creatinine Clearance < 30 mL/min) or moderate to severe hepatic impairment. Use is also prohibited if the patient is currently taking strong inhibitors or strong inducers of the CYP3A enzyme, as defined in the official label.
Restricted/Not Recommended Use	Use in the pediatric population (under 18 years) is not recommended because safety and efficacy have not been established. Similarly, use during pregnancy and breastfeeding is not recommended. Caution is required, and dose titration is advised, for older adults, patients with low body weight (le 60 kg), mild renal or hepatic impairment, or those with a history of Long QT Syndrome.

These criteria define the official boundaries for use, ensuring that only individuals who meet the eligibility and risk profile criteria outlined in the regulatory prescribing information are considered.

The official interaction profile of RANCOR (ranolazine) is governed by its documented relationship with specific metabolic enzymes and drug transporters, which results in formal regulatory constraints.

Prohibited Combinations

Co-administration with strong inhibitors of the CYP3A enzyme system (e.g., Ketoconazole, HIV Protease Inhibitors) and strong CYP3A inducers (e.g., Rifampicin, St. John’s Wort) is formally contraindicated. This is due to the significant resulting modification of ranolazine’s plasma concentration. Additionally, RANCOR is contraindicated with specific Class Ia and certain Class III antiarrhythmic medicines (e.g., Dofetilide, Quinidine) due to an additive pharmacodynamic risk of QTc interval prolongation.

Dose Restriction Requirements

When RANCOR is co-administered with moderate CYP3A inhibitors (such as Diltiazem or Verapamil), the regulatory documentation mandates a specific maximum dose limit for RANCOR to manage the resulting increase in exposure. Similarly, RANCOR is documented as inhibiting the P-glycoprotein (P-gp) and OCT2 transporters. This necessitates official dose restrictions for co-administered medicines that are substrates for these transporters, including Simvastatin, Digoxin, and Metformin.

Substance and Population Notes

Consumption of products like Grapefruit juice is restricted due to its potent CYP3A inhibitory effects. Use is also officially contraindicated in patients with severe hepatic or severe renal impairment due to the inherent risk of greatly increased ranolazine exposure in these populations.

How RANCOR Works

RANCOR (Ranolazine) exerts its pharmacological effect by a targeted, non-hemodynamic mechanism focused on modulating the ionic environment of the cardiac muscle. Its action is a direct cascade, originating from selective ion channel inhibition to modulated mechanical and metabolic efficiency.

1. Targeted Inhibition of the Late Sodium Current ( I Na,late)

Ranolazine acts as a selective inhibitor of the pathological persistent late inward sodium current ( I Na,late) found in heart cells under conditions of stress. This intervention is the molecular cornerstone of the mechanism, specifically aimed at modulating the excessive ion flow associated with pathological electrical events.

2. Stabilization of Intracellular Ca^2+ Homeostasis

The primary consequence of blocking I Na,late is the indirect prevention of intracellular calcium ( Ca^2+) overload. By limiting the upstream sodium influx, the drug prevents the secondary accumulation of calcium mediated by the sodium-calcium exchanger (NCX), thereby contributing to the stabilization of critical ion gradients.

3. Modulation of Diastolic Tension and MVO2

The normalized Ca^2+ handling is associated with a reduction in passive tension during the heart's relaxation phase (diastole), modulating mechanical efficiency. This enhanced efficiency directly reduces the heart muscle's demand for oxygen ( MVO2), representing a key pathway for favorable energetic modulation within the myocardium.

Official Administration Guidelines for РАНКОФ (Ranolazine)

These guidelines detail the prescribed method for using Ranolazine and apply strictly to the Extended-Release (ER) tablet formulation.

Core Administration Instructions

Instruction Category	Official Requirement
Route of Administration	Oral.
Dosage Form	Extended-Release Tablets (e.g., 500 mg, 1000 mg).
Starting & Maximum Dose	Start with 500 mg twice daily (BID). Maximum dose is 1000 mg BID.
Frequency and Timing	Take twice a day (approximately every 12 hours), with or without food.
Tablet Integrity	Swallow the tablet whole. The ER tablet must not be crushed, broken, or chewed.

Dose Management and Special Conditions

Dose Titration: The initial 500 mg BID dose may be increased to 1000 mg BID based on the patient's clinical needs.

Missed Dose: If a dose is missed, the patient should skip that dose and take the next scheduled dose at the usual time. Do not double the dose to compensate.

Mandatory Adjustment: A dosage constraint is required for specific co-administration. The maximum dose must be limited to 500 mg twice daily when taken with moderate inhibitors of the CYP3A enzyme (e.g., diltiazem, verapamil). Concomitant use with strong CYP3A inhibitors is contraindicated.

Special Population Note: Caution and careful dose titration are advised for elderly patients. The drug is not indicated for the acute treatment of an anginal episode; it is intended for long-term, chronic use.

Research evidence / Overview of Studies for RANCOR (Ranolazine)

---

Evidence for Use in Chronic Stable Angina (Add-on Therapy)

RANCOR was studied for its use in patients with chronic stable angina, a condition where research examined outcomes related to physical discomfort and functional limitations. The primary evidence comes from multiple short-term Randomized Controlled Trials (RCTs). In these trials, RANCOR was evaluated in adults who were already receiving other standard anti-anginal medications, focusing on its use as add-on therapy. Researchers primarily monitored patient-reported outcomes describing perceived discomfort, focusing on the average weekly number of angina episodes and the need for short-acting relief medications (nitrates). Functional outcomes reflecting daily functioning or activity level, such as total exercise duration on a treadmill test, were also studied for measurements of change.

The findings from these short-term studies describe patterns observed in the studies where research examined measurements showing fewer average weekly angina episodes compared to placebo. The research also monitored the consumption of short-acting nitrates, where findings describe observed patterns. Measurements of functional outcomes, such as total exercise duration, studies reported measurements related to longer duration in the observed populations receiving RANCOR.

---

Studies in Specific Patient Groups

Research has explored the use of RANCOR in specific populations where symptoms may vary in intensity. For instance, RANCOR was evaluated in chronic stable angina patients who also have Type 2 Diabetes Mellitus. Studies exploring short-term symptom changes data show patterns related to symptom frequency and functional capacity in this group.

Beyond the core patient population, RANCOR was studied for its application in patients with Coronary Microvascular Dysfunction (CMD). Research here relies on a smaller number of small-scale randomized controlled trials. These studies primarily examined physiological outcomes related to systemic or functional imbalance. Findings from this limited research was observed in some studies where data show patterns related to these physiological markers and certain patient-reported outcomes describing perceived discomfort. However, the sample sizes were modest, meaning certainty remains low regarding the clinical significance for this specific patient group.

---

What the Research Is Still Exploring (Evidence Gaps)

Official research bodies and peer-reviewed literature acknowledge several areas where evidence is still emerging or is limited.

One key area is the use of RANCOR as a single agent (monotherapy). Since the primary high-quality evidence focused on its use as an add-on to other therapies, comparative evidence is lacking for its use when evaluated alone as a first-line treatment option. Furthermore, because the core efficacy trials have limited information for long-term outcomes, the long-term consistency of the medicine's effects beyond the first few months of treatment is not fully established.

Common questions about РАНКОФ (FAQ)

Q: How quickly can people expect to feel the effects of РАНКОФ?

According to the official product information, Ranolazine is an extended-release tablet designed to release the active ingredient slowly over time. Peak plasma concentration is indicated to be reached 2 to 6 hours after a dose. Consistent levels, known as 'steady-state,' are generally indicated to be reached within three days of regular administration.

Q: Does РАНКОФ interact with common over-the-counter pain medications?

Regulatory documents note that Ranolazine is processed by certain enzymes and can affect transporters in the body. While specific over-the-counter pain medications are not always listed, official labeling notes the theoretical potential for interaction with other medications that are substrates for these specific enzyme systems and transporters.

Q: Is there a different way РАНКОФ is used compared to similar medicines?

Official documents describe Ranolazine as an anti-anginal medicine that is approved to be used by itself or alongside other standard treatments. Its mechanism of action is described as non-hemodynamic, meaning it functions through mechanisms that do not primarily involve changes in heart rate or blood pressure.

Q: Is it true that you must avoid alcohol completely while taking РАНКОФ?

Official drug information suggests that the consumption of alcohol while using Ranolazine may lead to potential interactions. This is noted in product guidelines to help reduce the risk of adverse events.

Q: Is it normal to not feel any effect immediately after starting РАНКОФ?

Yes, this is normal because Ranolazine is formulated as an extended-release medicine designed to build up stable levels in the body over time. Official pharmacokinetic data indicates that the expected steady-state concentration, where the anticipated therapeutic effects are established, is achieved after about three days of consistent administration.

Q: Are there any mental or mood changes associated with using РАНКОФ?

Official product safety information reports that adverse reactions can involve the nervous system. Specifically, regulatory documents report psychiatric issues such as a confusional state in some patients. Other related nervous system effects like dizziness and vertigo have also been noted in clinical data.

Q: Does РАНКОФ have any potential for misuse or dependence?

The official regulatory labeling for Ranolazine includes a section addressing drug abuse and dependence. According to this documentation, Ranolazine is generally not classified as a controlled substance and has not been documented as having a potential for misuse or physical dependence.

Q: Are there specific symptoms that mean I should stop taking РАНКОФ?

Official regulatory documents list rare, serious adverse events. These events, if observed, are serious adverse reactions listed in regulatory documents. They generally necessitate immediate medical evaluation, examples being signs of severe reactions such as angioedema, acute pancreatitis, and hepatitis.

Q: Are there any known interactions between РАНКОФ and birth control pills?

Ranolazine is documented to have an effect on certain metabolic enzymes (CYP3A4) and transporters (P-gp) in the body. Since some types of oral contraceptives are processed using these same systems, official labeling suggests a theoretical potential for an interaction that may affect the concentration of the contraceptive medicine.

Q: Are there any common reasons why a doctor might discontinue РАНКОФ?

Regulatory reports summarize the most common reasons why patients stopped taking the drug during clinical trials. The most frequently cited reasons for discontinuation were adverse events, including reactions such as dizziness, nausea, and headache.

Q: Can РАНКОФ affect the results of lab tests?

While the label does not specify interference with common diagnostic tests, official documents do report effects on measurable lab parameters. The drug has been associated with dose-related QTc interval prolongation (an electrical change in the heart) and has reported adverse events such as hematuria (blood in the urine).

Q: Are there any descriptive details about how РАНКОФ is absorbed by the body?

Regulatory pharmacokinetic documents provide details on how the drug is processed in the body. It is absorbed into the bloodstream and extensively metabolized, mainly by the liver and intestine. Official documents indicate that the absolute bioavailability of the tablet form is approximately 76%, and food consumption is not shown to significantly affect this absorption.

How to Store and Dispose of RANCOR (Ranolazine)

RANCOF (ranolazine extended-release tablets) must be stored strictly according to the conditions defined in the official regulatory label to ensure product stability.

Storage Requirements

The medication should be stored at a Controlled Room Temperature of 20 C to 25 C (68 F to 77 F), with permitted temperature excursions. It is mandatory to keep the tablets in a closed container and away from excessive heat, moisture, and direct light. The product must be protected from freezing and should not be used past the expiration date.

Child Safety and Disposal

The tablets must be stored out of the reach of children.

For disposal, do not throw away unused or expired Ranolazine via household waste or wastewater. Patients are required to consult a healthcare professional or pharmacist regarding the proper method for discarding the medicine according to local environmental regulations.